193 related articles for article (PubMed ID: 37900721)
1. Cost-Effectiveness Analysis of CT-Based Finite Element Modeling for Osteoporosis Screening in Secondary Fracture Prevention: An Early Health Technology Assessment in the Netherlands.
Li J; Viceconti M; Li X; Bhattacharya P; Naimark DMJ; Osseyran A
MDM Policy Pract; 2023; 8(2):23814683231202993. PubMed ID: 37900721
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Virtual Bone Strength Testing in Osteoporosis Screening Programs for Postmenopausal Women in the United States.
Agten CA; Ramme AJ; Kang S; Honig S; Chang G
Radiology; 2017 Nov; 285(2):506-517. PubMed ID: 28613988
[TBL] [Abstract][Full Text] [Related]
3. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
Ito K
JAMA Netw Open; 2020 Dec; 3(12):e2027584. PubMed ID: 33258906
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
Nayak S; Roberts MS; Greenspan SL
Ann Intern Med; 2011 Dec; 155(11):751-61. PubMed ID: 22147714
[TBL] [Abstract][Full Text] [Related]
6. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
Nayak S; Roberts MS; Greenspan SL
PLoS One; 2012; 7(3):e32879. PubMed ID: 22427903
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of fracture liaison services: a Markov model using Dutch real-world data.
Li N; van den Bergh JP; Boonen A; Wyers CE; Bours SPG; Hiligsmann M
Osteoporos Int; 2024 Feb; 35(2):293-307. PubMed ID: 37783759
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Cost-Effectiveness of Osteoporosis Screening With Dual-Energy X-ray Absorptiometry.
Hsu CL; Wu PC; Yin CH; Chen CH; Lee KT; Lin CL; Shi HY
Korean J Radiol; 2023 Dec; 24(12):1249-1259. PubMed ID: 38016684
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.
Ito K; Leslie WD
Osteoporos Int; 2015 Aug; 26(8):2111-9. PubMed ID: 25807913
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China.
You R; Zhang Y; Wu DB; Liu J; Qian X; Luo N; Mori T
Front Pharmacol; 2020; 11():456. PubMed ID: 32425768
[TBL] [Abstract][Full Text] [Related]
12. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.
Si L; Winzenberg TM; Chen M; Jiang Q; Neil A; Palmer AJ
Osteoporos Int; 2016 Jul; 27(7):2259-2269. PubMed ID: 26815042
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Moriwaki K; Mouri M; Hagino H
Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX
Martin-Sanchez M; Comas M; Posso M; Louro J; Domingo L; Tebé C; Castells X; Espallargues M
Calcif Tissue Int; 2019 Sep; 105(3):263-270. PubMed ID: 31172231
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Osteoporosis Screening Strategies for Men.
Nayak S; Greenspan SL
J Bone Miner Res; 2016 Jun; 31(6):1189-99. PubMed ID: 26751984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
